As a qui tam suit alleging fraud against one of the biggest private contractors for the multibillion-dollar Medicare Part D prescription-drug program heads toward discovery, a federal judge has defined the parameters for the discovery process.
U.S. District Senior Judge Ronald Buckwalter of the Eastern District of Pennsylvania weighed the 30 affirmative defenses raised by defendant CVS Caremark and the 19 dismissals sought by the plaintiff, Anthony Spay. Buckwalter granted a handful of Spay’s motions to dismiss and let stand nearly 12 challenged affirmative defenses.
